The global influenza drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of influenza and growing awareness about the disease among people. The market is also driven by factors such as increasing number of cases of flu in children and adults, rising demand for antiviral drugs, and growing preference for oral over injectable drugs. However, high cost associated with these drugs may hamper the growth of this market during the forecast period.
Zanamivir accounted for a share of around 40% in 2017 owing to its efficacy against both seasonal and pandemic strains. Oseltamivir phosphate accounted for a share of around 30% owing to its efficacy against seasonal strains only while peramivir accounted for a share less than 10%. Zanamivir dominated the North America region followed by Europe while oseltamivir phosphate dominated Latin America followed by Asia Pacific region owing to higher prevalence rates in these regions respectively.
- Growing awareness about prevention methods for influenza and other respiratory diseases will also drive demand for Influenza Drugs.
- The increasing number of elderly population in developing countries will lead to an increase in demand for Influenza Drugs 5) Increasing incidence rates among children.
Industry Growth Insights published a new data on “Influenza Drugs Market”. The research report is titled “Influenza Drugs Market research by Types (Zanamivir, Oseltamivir Phosphate, Peramivir, Other Influenza Drugs), By Applications (Adults, Chidren), By Players/Companies Bristol-Myers Squibb], AstraZeneca, Eli Lilly, Roche, GlaxoSmithKline, Novartis, Pfizer, Sanofi Pasteur, Bayer, Celgene, Seqirus, Protein Sciences Corporation, Serum Institute of India, Emergent Biosolutions, BioCryst Pharmaceuticals, Alvogen”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Influenza Drugs Market Research Report
By Type
Zanamivir, Oseltamivir Phosphate, Peramivir, Other Influenza Drugs
By Application
Adults, Chidren
By Companies
Bristol-Myers Squibb], AstraZeneca, Eli Lilly, Roche, GlaxoSmithKline, Novartis, Pfizer, Sanofi Pasteur, Bayer, Celgene, Seqirus, Protein Sciences Corporation, Serum Institute of India, Emergent Biosolutions, BioCryst Pharmaceuticals, Alvogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Influenza Drugs Market Report Segments:
The global Influenza Drugs market is segmented on the basis of:
Types
Zanamivir, Oseltamivir Phosphate, Peramivir, Other Influenza Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Chidren
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb]
- AstraZeneca
- Eli Lilly
- Roche
- GlaxoSmithKline
- Novartis
- Pfizer
- Sanofi Pasteur
- Bayer
- Celgene
- Seqirus
- Protein Sciences Corporation
- Serum Institute of India
- Emergent Biosolutions
- BioCryst Pharmaceuticals
- Alvogen
Highlights of The Influenza Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Zanamivir
- Oseltamivir Phosphate
- Peramivir
- Other Influenza Drugs
- By Application:
- Adults
- Chidren
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Influenza Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Influenza drugs are medications used to treat influenza. These drugs can help reduce the severity of symptoms, shorten the duration of illness, and prevent complications from influenza.
Some of the major players in the influenza drugs market are Bristol-Myers Squibb], AstraZeneca, Eli Lilly, Roche, GlaxoSmithKline, Novartis, Pfizer, Sanofi Pasteur, Bayer, Celgene, Seqirus, Protein Sciences Corporation, Serum Institute of India, Emergent Biosolutions, BioCryst Pharmaceuticals, Alvogen.
The influenza drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Influenza Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Influenza Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Influenza Drugs Market - Supply Chain
4.5. Global Influenza Drugs Market Forecast
4.5.1. Influenza Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Influenza Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Influenza Drugs Market Absolute $ Opportunity
5. Global Influenza Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Influenza Drugs Market Size and Volume Forecast by Type
5.3.1. Zanamivir
5.3.2. Oseltamivir Phosphate
5.3.3. Peramivir
5.3.4. Other Influenza Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Influenza Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Influenza Drugs Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Chidren
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Influenza Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Influenza Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Influenza Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Influenza Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Influenza Drugs Demand Share Forecast, 2019-2026
9. North America Influenza Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Influenza Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Influenza Drugs Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Chidren
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Influenza Drugs Market Size and Volume Forecast by Type
9.7.1. Zanamivir
9.7.2. Oseltamivir Phosphate
9.7.3. Peramivir
9.7.4. Other Influenza Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Influenza Drugs Demand Share Forecast, 2019-2026
10. Latin America Influenza Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Influenza Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Influenza Drugs Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Chidren
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Influenza Drugs Market Size and Volume Forecast by Type
10.7.1. Zanamivir
10.7.2. Oseltamivir Phosphate
10.7.3. Peramivir
10.7.4. Other Influenza Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Influenza Drugs Demand Share Forecast, 2019-2026
11. Europe Influenza Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Influenza Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Influenza Drugs Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Chidren
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Influenza Drugs Market Size and Volume Forecast by Type
11.7.1. Zanamivir
11.7.2. Oseltamivir Phosphate
11.7.3. Peramivir
11.7.4. Other Influenza Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Influenza Drugs Demand Share, 2019-2026
12. Asia Pacific Influenza Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Influenza Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Influenza Drugs Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Chidren
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Influenza Drugs Market Size and Volume Forecast by Type
12.7.1. Zanamivir
12.7.2. Oseltamivir Phosphate
12.7.3. Peramivir
12.7.4. Other Influenza Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Influenza Drugs Demand Share, 2019-2026
13. Middle East & Africa Influenza Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Influenza Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Influenza Drugs Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Chidren
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Influenza Drugs Market Size and Volume Forecast by Type
13.7.1. Zanamivir
13.7.2. Oseltamivir Phosphate
13.7.3. Peramivir
13.7.4. Other Influenza Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Influenza Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Influenza Drugs Market: Market Share Analysis
14.2. Influenza Drugs Distributors and Customers
14.3. Influenza Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb]
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi Pasteur
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bayer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Celgene
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Seqirus
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Protein Sciences Corporation
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Serum Institute of India
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Emergent Biosolutions
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. BioCryst Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Alvogen
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
